Network Italiano Per la Bioterapia Dei Tumori

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Alexander Martens, Kilian Wistuba‐Hamprecht, Marnix Geukes Foppen et al. · Clinical Cancer Research · 2016 · 542 citations · Full text

Medicine, Immunology, Oncology +17

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 424 citations

Medicine, Oncology, Pharmacotherapy +11

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, David R. Spigel, Eric D. Whitman · The Lancet Oncology · 2018 · 216 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Anna Maria Di Giacomo, Paolo A. Ascierto, Paola Queirolo et al. · Annals of Oncology · 2014 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

Consensus nomenclature for CD8⁺T cell phenotypes in cancer

Lionel Apétoh, Mark J. Smyth, Charles G. Drake et al. · OncoImmunology · 2015 · 136 citations · Full text

Medicine, Immunology, Oncology +17